General Information of Drug (ID: DMWYU5C)

Drug Name
JNJ-5207787 Drug Info
Synonyms JNJ5207787
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
10324083
CAS Number
CAS 683746-68-1
TTD Drug ID
DMWYU5C

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Discontinued Drug(s)
Preclinical Drug(s)
Investigative Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
NEUROPEPTIDE-Y DMINQP1 N. A. N. A. Phase 2 [3]
TM30338 DMXNQLU Obesity 5B81 Discontinued in Phase 2 [4]
PYY3-36 DMTGFV6 Obesity 5B81 Discontinued in Phase 2 [5]
AC-162352 DME98LV Obesity 5B81 Discontinued in Phase 1 [5]
BMS-192548 DMHAWBR Obesity 5B81 Preclinical [5]
CIN-110 DMYMZQW Obesity 5B81 Preclinical [6]
H-[Trp-Arg-Nva-Arg-Tyr]3-NH2 DMKH8PF Discovery agent N.A. Investigative [7]
Sub[-Trp-Arg-Nva-Arg-Tyr-NH2]2 DM4SWQA Discovery agent N.A. Investigative [7]
Pim[-Trp-Arg-Nva-Arg-Tyr-NH2]2 DMBERSG Discovery agent N.A. Investigative [7]
Sub[-Tyr-Arg-Leu-Arg-Tyr-NH2]2 DM56MOV Discovery agent N.A. Investigative [7]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Neuropeptide Y receptor type 2 (NPY2R) TTJ6WK9 NPY2R_HUMAN Antagonist [2]

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 3504).
2 Characterization of N-(1-Acetyl-2,3-dihydro-1H-indol-6-yl)-3-(3-cyano-phenyl)-N-[1-(2-cyclopentyl-ethyl)-piperidin-4yl]acrylamide (JNJ-5207787), a ... J Pharmacol Exp Ther. 2004 Mar;308(3):1130-7.
3 cis-4-(Piperazin-1-yl)-5,6,7a,8,9,10,11,11a-octahydrobenzofuro[2,3-h]quinazolin-2-amine (A-987306), a new histamine H4R antagonist that blocks pain... J Med Chem. 2008 Nov 27;51(22):7094-8.
4 Anti-Obesity Drug Discovery and Development, Atta-ur- Rahman, page(108)
5 Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines. Expert Opin Emerg Drugs. 2005 Aug;10(3):643-60.
6 Clinical pipeline report, company report or official report of CinFina Pharma
7 Neuropeptide Y (NPY) Y4 receptor selective agonists based on NPY(32-36): development of an anorectic Y4 receptor selective agonist with picomolar a... J Med Chem. 2006 Apr 20;49(8):2661-5.